Jump to any asset
849 assets, updated daily
As of October 11, 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at $510.08. CleaRank Financial AI rates it Buy with a fair value of $577.50, 13.2% above the current price. Wall Street's consensus target is $577.50 across 32 analysts. RSI at 49 is in neutral territory, and the price is below its 50-day average of $520.46.
Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated NASDAQ
$510.08
6.830 (1.36%)
At close: Oct 9, 4:00 PM EDT
AI Analyst Consensus
73 / 100
Vertex Pharmaceuticals Incorporated (VRTX) is trading at $510.08, below its 50-day moving average of $520.46 but above its 200-day moving average of $474.90. The company operates in the Biotechnology sector, with a significant portion of its valuation supported by its strong profit margins and return on equity, which stand at 35.00% and 23.54% respectively, outperforming sector averages. Analyst sentiment remains positive, with a consensus 'Buy' rating and a median price target of $577.50, implying a 13.2% upside. While the company exhibits strong fundamental metrics, recent insider activity shows heavy net selling, with $622.7M in total sales versus $14.0M in total purchases, a factor that warrants investor attention.
VRTX Price Analysis
Market Metrics
Open
$502.11
Day Range
$502.06 to $514.90
Prev Close
$503.25
Volume
1.48M
52-Week Range
$384.39 to $560.25
Market Cap
$129.29B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (-7% difference), suggesting fair market pricing relative to industry standards.
VRTX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, VRTX beat estimates 2 times. However, the stock fell 2 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
VRTX Analysis
Company's Health
4/5
12-Month Analyst Target
+13.22% Upside
Median of 32 analysts (12-month)
$577.50
AI Technical Analysis
Vertex Pharmaceuticals Incorporated (VRTX) exhibits neutral momentum with an RSI of 49.42, indicating neither overbought nor oversold conditions. The stock is currently trading below its 20-day EMA of $514.08 and its 50-day SMA of $520.46, suggesting near-term weakness, but remains above its 200-day SMA of $474.90, indicating a longer-term uptrend. Volume has been above average recently, with the latest volume at 1.48 million compared to an average of 1.03 million. Key support is identified at the 200-day SMA of $474.90, while resistance may be encountered near the 50-day SMA of $520.46. The current chart structure suggests a consolidation phase within a broader upward trend.
ProTips
- Monitor insider transactions closely, as the recent heavy net selling by insiders warrants caution despite a generally positive analyst outlook.
- The stock's position below its 50-day SMA suggests potential for near-term consolidation or a pullback before resuming a significant upward trend.
- Given the strong revenue growth and profitability, consider dollar-cost averaging into the position to mitigate risks associated with the current technical setup and insider selling.
Key Catalysts
Bullish
Positive Analyst Ratings and Price Targets
32 analysts maintain a consensus 'Buy' rating with a median price target of $577.50, indicating strong conviction in Vertex Pharmaceuticals Incorporated's future performance.
Source: Wall Street AnalystsBullish
Strong Revenue Growth Projections
Vertex Pharmaceuticals Incorporated is projected to achieve 10.00% revenue growth for the current and next fiscal years, exceeding sector averages and signaling continued business expansion.
Source: Wall Street EstimatesBearish
Heavy Insider Selling Activity
Insiders have sold $157.5 million worth of stock versus only $5.8 million in purchases, indicating a net seller position and potentially raising concerns about management's short-term outlook.
Source: Insider TransactionsBearish
Trading Below 50-Day Moving Average
Vertex Pharmaceuticals Incorporated is currently trading below its 50-day Simple Moving Average of $520.46, which could signal a near-term trend reversal or increased selling pressure.
Source: Technical AnalysisMarket Outlook
Vertex Pharmaceuticals Incorporated (VRTX) is expected to see continued growth, with analysts projecting a median price target of $577.50, representing a 13.2% upside from current levels. The company's strong profit margins, healthy balance sheet, and above-sector-average revenue growth provide a solid foundation for this outlook. Potential upside catalysts include successful pipeline advancements and continued strong revenue growth, as indicated by next year's projected EPS of $20.22 and 5-year average growth of 18.6%. However, the significant insider selling and the stock's current position below its 50-day moving average present near-term risks that could temper performance.
Key Statistics
| Market Cap | 129.29B |
|---|---|
| P/E Ratio | 29.72 |
| EPS (TTM) | 17.17 |
| Dividend Yield | 0.00% |
| 52 Week High | 560.25 |
| 52 Week Low | 384.39 |
Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/E ratio of 29.72, which is slightly below the sector average of 31.9, indicating a potentially reasonable valuation relative to its peers. Its Price-to-Sales ratio stands at 10.28, also suggesting it is not excessively overvalued given its strong profitability. The company demonstrates strong financial health with a profit margin of 35.00% and an operating margin of 38.06%, significantly exceeding the sector averages of 6.9% for ROE. Its debt-to-equity ratio is a healthy 0.10, indicating low financial leverage. Revenue growth of 12.5% also surpasses the sector average of 8.1%, pointing to consistent expansion.
Earnings & Growth Analysis
Vertex Pharmaceuticals Incorporated (VRTX) most recently reported earnings for the quarter ending June 2026, with an actual EPS of $4.73 against an estimate of $4.75, a slight miss of -0.42%, leading to a 1.7% price increase. Prior quarters show a mixed performance, including a significant miss in the quarter ending March 2026 (-14.29% surprise) and a beat in the quarter ending March 2026 (+6.67% surprise). Forward estimates suggest a challenging current quarter with an average EPS estimate of $-0.74, but a rebound is projected for the next quarter ($4.59) and subsequent years, with next year's EPS estimated at $20.22. Revenue growth is anticipated to remain strong at approximately 10% for the current and next fiscal years.
Key Risks
A significant risk for Vertex Pharmaceuticals Incorporated (VRTX) is the heavy insider selling, with over $157 million in dispositions versus only $5.8 million in purchases, signaling potential concerns among management. While the stock is trading above its 200-day moving average, it is currently below its 50-day moving average, indicating potential near-term headwinds. Also, the current quarter's EPS estimate of $-0.74, although a projection, contrasts with positive earnings in prior periods and warrants close monitoring of future guidance and earnings reports.
Technical Indicators
| RSI (14) | 49.42 |
|---|---|
| MACD | -4.58 |
| SMA 50 | 520.46 |
| SMA 200 | 474.90 |
RSI
Neutral
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($520.46) above the 200-day SMA ($474.90), price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.25
Weak correlation
Nasdaq 100 (QQQ)
+0.20
Weak correlation
Bitcoin (BTC)
-0.03
Weak correlation
Gold (XAU)
+0.11
Weak correlation
Check Custom Correlation
How does any other asset move with VRTX? One year of daily closes, Pearson correlation.
Try
VRTX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$499.88
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$510.08
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$480.68
MAX LOSS
-3.8%
Volatility-Adjusted Stop Loss
Calculated based on RSI (49.4) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$524.87
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$549.87
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$574.86
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for VRTX is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on October 11, 2026.Growth of $10,000
A $10,000 investment in VRTX in October 2016 would be worth about $62,464 today, compared with about $36,479 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in VRTX today could grow to about $33,588 by 2036 in the base case, with a bull case near $125,962 and a bear case around $8,956. Projections are statistical simulations, not guarantees.
VRTX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $828 for VRTX by 2030 in the base case, from $510 today (1.6x over 4 years). The downside path ends near $359. These are outcomes of a Monte Carlo simulation run on VRTX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $379 | $576 | $875 |
| 2028 | $360 | $650 | $1,174 |
| 2029 | $356 | $734 | $1,513 |
| 2030 | $359 | $828 | $1,911 |
| 2031 | $367 | $935 | $2,380 |
| 2032 | $379 | $1,055 | $2,938 |
| 2033 | $394 | $1,191 | $3,600 |
| 2034 | $412 | $1,345 | $4,386 |
| 2035 | $433 | $1,518 | $5,319 |
| 2036 | $457 | $1,713 | $6,425 |
Method: 10,000 simulated price paths using VRTX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
VRTX Insider Trading Analysis
Bought
$5.8M
2 Transactions
Sold
$157.5M
55 Transactions
Insiders
23
Active Traders
Avg Transaction
$2.9M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jul 25, 2022 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 132.1K | $37.2M |
| Nov 14, 2025 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 73.3K | $32.3M |
| Dec 3, 2025 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 63.8K | $28.7M |
| Feb 19, 2026 | SACHDEV AMIT
Officer
|
Sell | 58.6K | $27.5M |
| May 12, 2020 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 94.4K | $26.8M |
| May 5, 2020 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 94.4K | $25.5M |
| May 7, 2020 | LEIDEN JEFFREY M
Officer and Director
|
Sell | 94.4K | $25.5M |
| Feb 27, 2026 | KEWALRAMANI RESHMA
Chief Executive Officer
|
Sell | 40.0K | $19.7M |
| May 5, 2020 | SACHDEV AMIT
Officer
|
Sell | 57.1K | $15.1M |
| May 7, 2020 | SACHS BRUCE I
Director
|
Sell | 45.0K | $12.1M |
Page 1 of 1
Frequently Asked Questions
Is Vertex Pharmaceuticals Incorporated (VRTX) stock a buy right now?
Vertex Pharmaceuticals Incorporated (VRTX) is currently rated a 'Buy' with a consensus score of 73. The median analyst price target is $577.50, suggesting a potential upside of 13.2% from the current price of $510.08. However, significant insider selling should be considered.
What is Vertex Pharmaceuticals Incorporated's (VRTX) stock price forecast for 2030?
Based on Monte Carlo simulations, Vertex Pharmaceuticals Incorporated's (VRTX) stock price forecast for 2030 includes a base case of $828.15 and a downside case of $358.96. These are statistical outcomes, not guarantees.
How does Vertex Pharmaceuticals Incorporated (VRTX) compare to its sector averages?
Vertex Pharmaceuticals Incorporated (VRTX) shows a P/E ratio of 29.72 compared to the Healthcare sector average of 31.9. Its revenue growth of 12.5% exceeds the sector average of 8.1%, and its profit margin of 35.00% is substantially higher than the sector's ROE of 6.9%.
What are the recent earnings trends for Vertex Pharmaceuticals Incorporated (VRTX)?
Vertex Pharmaceuticals Incorporated (VRTX) recently reported a slight EPS miss for the quarter ending June 2026. While past performance has been mixed, forward estimates indicate a rebound in earnings for the next quarter and year, with projected EPS of $4.59 and $20.22 respectively.
What is the technical outlook for Vertex Pharmaceuticals Incorporated (VRTX)?
Vertex Pharmaceuticals Incorporated (VRTX) shows neutral RSI momentum (49.42) and is trading below its 50-day SMA but above its 200-day SMA. Recent volume has been above average, suggesting investor interest during this consolidation phase.
What are the main risks facing Vertex Pharmaceuticals Incorporated (VRTX)?
The primary risks for Vertex Pharmaceuticals Incorporated (VRTX) include substantial insider selling totaling over $157 million and the stock trading below its 50-day moving average. Additionally, the projected negative EPS for the current quarter warrants close observation.
What is the projected revenue growth for Vertex Pharmaceuticals Incorporated (VRTX)?
Vertex Pharmaceuticals Incorporated (VRTX) is projected to achieve revenue growth of approximately 10.00% for the current and next fiscal years. Next quarter's revenue is estimated to grow by 11.00% year-over-year.